HC Wainwright Estimates SOPHiA GENETICS Q2 Earnings

Key Points

• HC Wainwright initiated/maintained a Buy rating on SOPHiA GENETICS with a $12 price target, implying meaningful upside from the stock’s recent trading level around $6.50.
• The firm expects SOPHiA GENETICS to post a Q2 2026 loss of $0.15 per share; its forecasts remain negative through FY2027, with profitability not expected until FY2028.
• The company’s last reported quarter also showed a EPS miss at $(0.27) versus expectations of $(0.23), though revenue of $21.69 million came in above consensus.

SOPHiA GENETICS SA (NASDAQ:SOPH - Free Report) - Equities researchers at HC Wainwright issued their Q2 2026 earnings estimates for SOPHiA GENETICS in a research note issued to investors on Monday, July 20th. HC Wainwright analyst S. Ramakanth expects that the company will earn ($0.15) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $12.00 price target on the stock. HC Wainwright also issued estimates for SOPHiA GENETICS's Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.05) EPS, FY2026 earnings at ($0.58) EPS, Q1 2027 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.01) EPS, FY2027 earnings at ($0.20) EPS, FY2028 earnings at $0.04 EPS, FY2029 earnings at $0.34 EPS and FY2030 earnings at $0.69 EPS.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last announced its earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. The company had revenue of $21.69 million for the quarter, compared to the consensus estimate of $20.40 million.

A number of other research firms also recently weighed in on SOPH. Weiss Ratings restated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research report on Friday. BTIG Research reiterated a "buy" rating and set a $8.00 price objective on shares of SOPHiA GENETICS in a research report on Monday, June 15th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, SOPHiA GENETICS presently has a consensus rating of "Moderate Buy" and an average target price of $9.00.

SOPHiA GENETICS Stock Performance

SOPHiA GENETICS stock opened at $6.50 on Wednesday. SOPHiA GENETICS has a fifty-two week low of $2.92 and a fifty-two week high of $6.74. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.90 and a current ratio of 2.06. The stock has a market cap of $545.28 million, a P/E ratio of -12.50 and a beta of 0.96. The firm's fifty day moving average price is $5.30 and its 200-day moving average price is $5.05.

Insider Activity at SOPHiA GENETICS

In related news, CEO Ross Muken sold 9,838 shares of SOPHiA GENETICS stock in a transaction on Monday, July 6th. The shares were sold at an average price of $5.22, for a total value of $51,354.36. Following the transaction, the chief executive officer owned 670,651 shares in the company, valued at $3,500,798.22. This trade represents a 1.45% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Zhenyu Xu sold 7,393 shares of SOPHiA GENETICS stock in a transaction on Monday, July 6th. The stock was sold at an average price of $5.17, for a total transaction of $38,221.81. Following the completion of the transaction, the insider owned 614,887 shares in the company, valued at approximately $3,178,965.79. The trade was a 1.19% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 176,711 shares of company stock worth $959,913 in the last 90 days. Corporate insiders own 4.88% of the company's stock.

Institutional Investors Weigh In On SOPHiA GENETICS

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in SOPHiA GENETICS by 246.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company's stock worth $25,341,000 after acquiring an additional 5,432,871 shares during the last quarter. Akre Capital Management LLC lifted its position in SOPHiA GENETICS by 66.2% in the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company's stock valued at $11,529,000 after purchasing an additional 1,481,636 shares during the last quarter. Hodges Capital Management Inc. purchased a new stake in shares of SOPHiA GENETICS during the first quarter valued at approximately $2,157,000. Royce & Associates LP purchased a new stake in shares of SOPHiA GENETICS during the fourth quarter valued at approximately $2,009,000. Finally, Sei Investments Co. bought a new position in shares of SOPHiA GENETICS in the first quarter worth approximately $1,772,000. Institutional investors own 31.59% of the company's stock.

More SOPHiA GENETICS News

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: HC Wainwright initiated coverage on SOPHiA GENETICS SA with a Buy rating and $12 price target, signaling strong upside potential versus the current trading level. Street Insider analyst coverage article
• Positive Sentiment: HC Wainwright’s longer-term estimates call for SOPHiA GENETICS to move from losses to profitability by FY2028 and stronger earnings in FY2029-FY2030, which could reinforce a growth narrative for the stock.
• Neutral Sentiment: The company said it will report second-quarter 2026 results on August 4, which is a key near-term catalyst but does not by itself change fundamentals. PR Newswire earnings date announcement
• Neutral Sentiment: Management also highlighted AI-driven precision medicine in a recent media appearance, which may support the company’s growth story but is not a direct financial update. MSN interview article
• Negative Sentiment: HC Wainwright’s near-term EPS estimates remain negative through FY2027, suggesting SOPHiA GENETICS is still expected to burn cash before reaching profitability.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.